Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 201-208

  Gadducci, Angiolo ^a   Teti, Giancarlo ^a   Barsotti, Cecilia ^a   Tana, Roberta ^a   Fanucchi, Antonio ^a   Orlandini, Cinzia ^b   Fabrini, Maria Grazia ^b   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Cervical cancer; Lymph node involvement; Lymph vascular space involvement; Neoadjuvant chemotherapy; Platelet count; Radical hysterectomy

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; IFOSFAMIDE; MESNA; PACLITAXEL; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADICAL HYSTERECTOMY; THROMBOCYTE COUNT; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77649261743     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Rose PG: Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs 60: 1239-1244, 2000.
2. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Nyan HYS and Pecorelli S: Carcinoma of the uterine cervix. Int J Gynecol Obstet 95(Suppl 1): S43-104, 2006.
3. Rose PG: Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006? Ann Oncol 17(Suppl 10): 224-229, 2006.
4. Vale C, Tierney JF, Stewart LA, Brady M, Dinshaw K, Jakobsen A, Parmar MK, Thomas G, Trimble T, Alberts DS, Chen H, Cikaric S, Eifel PJ, Garipagaoglu M, Keys H, Kantardzic N, Lal P, Lanciano R, Leborgne F, Lorvidhaya V, Onishi H, Pearcey RG, Pras E, Roberts K, Rose PG, Thomas G and Whitney CW.Chemoradiotherapy for Cervical Cancer Meta-Analysis. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26: 5802-5812, 2008.
5. Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez Rueda N and di Paola G: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results.. Gynecol Oncol 67: 61-69, 1997.
6. Benedetti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, Cutillo G, Paratore MP, Scorpiglione N and Mancuso S: Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 34: 341-346, 1998.
7. Neoadjuvant chemotherapy for cervical cancer meta-analysis collaboration (NACCCMA) collaboration: Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2: CD001774, 2004.
8. González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A and Chiva LM: The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecol Oncol 110(3 Suppl 2): S36-40, 2008.
9. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C and Landoni F: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20: 179-188, 2002.
10. Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P and Mangioni C: Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23: 4137-4145, 2005.
11. Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chari S, Buda A, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V and Rulli E: A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP-02 Italian Collaborative Study. Ann Oncol 20: 660-665, 2009.
12. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, Switzerland, WHO, 1979. http://whqlibdoc.who.int/publications/9241700483.pdf
13. Kim DS, Moon H, Kim KT, Hwang YY, Cho SH and Kim SR: Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor. Gynecol Oncol 33: 225-230, 1989.
14. Giaroli A, Sananes C, Sardi JE, Maya AG, Bastardas ML, Snaidas L, Rueda NG, Vighi S and di Paola GR: Lymph node metastases in carcinoma of the cervix uteri: response to neoadjuvant chemotherapy and its impact on survival. Gynecol Oncol 39: 34-39, 1990.
15. Colombo N, Gabriele A, Lissoni A, Vecchione F, Zanetta G, Pellegrino A, Maneo A, Floriani I and Landoni F: Neoadjuvant chemotherapy (NACT) in locally advanced uterine cervical cancer (LAUCC): Correlation between pathological response and survival. Proc Am Soc Clin Oncol 17: 352a, (abstr 1359), 1998.
16. Nashiltz JE, Yeshurun D, Eldar S and Lev LM: Diagnosis of cancer-associated vascular disorder. Cancer 77: 1759-1767, 1996.
17. Costantini V, Zacharski LR, Moritz TE, and Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb Haemost 64: 501-505, 1990.
18. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F and Patard JJ: Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175: 859-863, 2006.
19. Scholz HS, Petru E, Gücer F, Haas J, Tamussino K and Winter R: Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 20: 3983-3985, 2000.
20. Hernandez E, Lavine M, Dunton CJ, Gracely E and Parker J: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 69: 2975-2977, 1992.
21. Lopes A, Daras V, Cross PA, Robertson G, Beynon G and Monaghan JM: Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 74: 90-92, 1994.
22. Rodriguez G: Does thrombocytosis have any prognostic significance in cervical cancer? Gynecol Oncol 55: 325-327, 1994.
23. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I and Dodge RK: The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 83: 445-448, 1994.
24. De Jonge ET, Viljoen E, Lindeque BG, Amant F, Nesland JM and Holm R: The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy. Int J Gynecol Cancer 9: 198-205, 1999.
25. Hernandez E, Donohue KA, Anderson LL, Heller PB and Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78: 137-142, 2000.
26. Kirnbauer R, Köck A, Schwarz T, Urbanski A, Krutmann J, Borth W, Damm D, Shipley G, Ansel JC and Luger TA: IFN-b2, B-cell differentiation factor 2,or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol 142: 1922-1928, 1989.
27. Rawle FC, Shields J, Smith SH, Iliescu V, Merkenschlager M, Beverley PC and Callard RE: B cell growth and differentiation induced by supernatants of transformed epithelial cell lines. Eur J Immunol 16: 1017-1019, 1986.
28. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T and Kishimoto T: Interleukin 6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 250: 607-610, 1989.
29. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF and Pinedo HM: Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221, 2000.
30. Munson L, Upadhyaya NB and Van Meter S: Platelet-derived growth factor promotes endometrial epithelial cell proliferation. Am J Obstet Gynecol 173: 1820-1825, 1995.
31. Featherstone C: Aspirin for bowel cancer: an old friend finds a new role. Lancet 350: 418, 1997.
32. Salven P, Orpana A and Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5: 487-491, 1999.
33. Dicato M: Anemia in cancer: some pathophysiological aspects. Oncologist 8(Suppl 1): 19-21, 2003.
34. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J and Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536, 1999.
35. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H and Haensgen S: Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56: 778-787, 2003.
36. Obermair A, Cheuk R, Horwood K, Neudorfer M, Janda M, Giannis G, Nicklin JL, Perrin LC and Crandon AJ: Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. Int J Gynecol Cancer 13: 633-639, 2003.
37. Cho EI, Sasaki CT and Haffty BG: Prognostic significance of pretreatment hemoglobin for local control and overall survival in T1-T2N0 larynx cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 58: 1135-1140, 2004.
38. Winter WE 3rd, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G and Carlson JW: Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 94: 495-501, 2004.
39. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Colombo N, Fanucchi A, Chiudinelli F, Lapresa M and Maria Ferrero A: Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. Gynecol Oncol 98: 118-123, 2005.
40. Serkies K, Badzio A and Jassem J: Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy. Acta Oncol 45: 695-701, 2006.
41. Van Belle SJ and Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 47: 1-11, 2003.
42. Fuso L, Mazzola S, Marocco F, Ferrero A, Dompè D, Carus AP and Zola P: Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report. Gynecol Oncol 99(Suppl 1): S187-191, 2005.
43. Bellati F, Pernice M, Manci N, Palaia I, Tomao F, Marchetti C, Zullo MA, Muzii L, Angioli R and Benedetti Panici P: Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neoadjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Ann Oncol 18: 722-729, 2007.